“It is necessary to review the stability pact with a correct and realistic forecast of expenditure, calculated on the appropriateness of the treatments offered. The current mechanism of the pharmaceutical expenditure ceiling, rigid and which does not take into account the growing demand for health of Italians, the aging of the population and the transfer of pharmaceutical assistance from the hospital to the territory must be overcome”. The president of Farmindustria said it, Sergio Dompè, in his speech at the public meeting of the association of drug companies. These are the necessary conditions, according to the number one of Farmindustria, “to make our country competitive, maintaining company investments and attracting new ones. Conditions - he adds - which must necessarily be accompanied by a precise and convinced policy of relaunching research with incentives for those who invest. Pharmaceutical companies want to responsibly confirm their commitment – Dompè assures – in favor of the growth of innovation and technological culture in Italy, but they must be able to look to the future with confidence, consolidating and multiplying current investments in the country”.
